News

iQSTEL Expands Financial Horizons with Convertible Note Extension

iQSTEL Expands Financial Horizons with Convertible Note Extension

Introduction to iQSTEL's Growth Strategy

iQSTEL Inc. (NASDAQ: IQST), a leading force in the telecommunications and technology sector, has secured an important 12-month extension on its convertible notes with M2B Funding Corp. This milestone marks a significant step in iQSTEL's ambitious journey towards achieving a Nasdaq uplisting, further reinforcing the company’s growth trajectory.

Strengthening Investor Confidence

The unwavering support from investors has played a critical role in iQSTEL’s recent success. Over the past six years, the company has focused on innovative solutions that not only meet current technology needs but also anticipate future demands. This extension of convertible notes is a strong indicator of investor trust in iQSTEL’s strategic direction and long-term objectives.

CEO's Vision for the Future

Leandro Jose Iglesias, the CEO of iQSTEL, expressed the company’s commitment to leveraging established relationships with major telecom firms worldwide. "Our investors recognize the significant potential within iQSTEL. They believe in our comprehensive strategy and ambitious vision. We aim to drive substantial growth through high-margin solutions designed for a rapidly evolving market," said Iglesias.

Details and Implications of Note Extensions

This strategic move involved extending the maturity dates of three key convertible notes, thereby securing vital funding for ongoing growth initiatives. The first convertible note, previously due on January 1, 2025, is now extended to January 1, 2026, with an outstanding amount of $1,888,888.89. Similarly, the second note, originally due on March 12, 2025, has been extended to March 12, 2026, and the third note, due on March 25, 2025, is now due on March 25, 2026. The issuance of restricted common stock to M2B Funding Corp. further solidifies this financial partnership.

Innovations and Partnerships Driving iQSTEL Forward

iQSTEL is on the brink of revolutionizing several sectors with its innovative partnerships and technology offerings. An example of this innovation is the recent collaboration with Cycurion to provide advanced cybersecurity solutions tailored for telecom clients. This collaboration ensures that iQSTEL remains at the forefront of industry advancements, capturing new revenue streams while enhancing service offerings.

Expanding Market Presence

Moreover, the partnership with ONAR, a leading marketing agency, is set to elevate iQSTEL's branding and global presence. With ONAR’s support, the company aims to communicate its growth narrative effectively and attract new investors, ensuring that iQSTEL's story of innovation resonates widely.

Ambitious Revenue Goals

iQSTEL is setting its sights high with targets to achieve $1 billion in revenue by 2027. In 2023, the company reported revenues of $144 million, with projections for 2024 indicating revenues of $290 million. This growth trajectory showcases iQSTEL’s robust business strategy and operational success, making it a formidable player in the tech sector.

Innovative Product Portfolio

At the heart of iQSTEL’s operations is a diverse portfolio that includes telecommunications services, fintech solutions, electric vehicles, artificial intelligence, and cybersecurity. The company continues to expand its reach, fueled by a series of strategic acquisitions aimed at enhancing its market position and service capabilities.

Conclusion: A Future Full of Promise

As iQSTEL embarks on its next chapter, the company remains dedicated to transforming industries through innovation. With a clear path toward Nasdaq uplisting and robust growth plans, iQSTEL is positioning itself to capitalize on emerging opportunities. This is a pivotal moment for the company, and all eyes are on iQSTEL as it moves forward in its quest for excellence in telecommunications and tech solutions.

Frequently Asked Questions

What is the significance of the convertible note extension for iQSTEL?

The extension provides iQSTEL with additional time and financial support to execute its growth strategy, aiding its push for a Nasdaq uplisting.

Who is leading iQSTEL and what is their vision?

Leandro Jose Iglesias is the CEO and President, focusing on fostering strategic partnerships to drive growth and expansion in the technology sector.

What industries is iQSTEL involved in?

iQSTEL operates in telecommunications, fintech, electric vehicles, AI services, and cybersecurity, offering a wide array of innovative solutions.

How much revenue does iQSTEL aim to achieve by 2027?

iQSTEL aims to reach $1 billion in revenue by 2027, building on its strong financial trajectory and market presence.

What are iQSTEL's recent strategic partnerships?

Recent partnerships include collaborations with Cycurion for cybersecurity solutions and ONAR for enhancing marketing and branding efforts.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 308

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 9

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 26

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 321

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading

Top 5 Most Recently Viewed Articles

BioSyent Inc. to Announce Q3 Financial Results This Month

Updated Category News Views 189

BioSyent Inc. to Announce Q3 Financial Results BioSyent Inc., a prominent player in the specialty pharmaceutical industry, is preparing to release its financial results for the third quarter and year-to-date period. This important announcement is scheduled for November 20, prior to the market opening. The report will cover the company's performance for the three and nine...

Continue Reading
Dr. Ryan Egeland Joins Solventum as Chief Medical Officer

Updated Category News Views 381

Solventum Welcomes Dr. Ryan Egeland as New CMO Solventum, a pioneering healthcare company, recently announced the appointment of Dr. Ryan Egeland, MD, as their Chief Medical Officer. In this significant role, Dr. Egeland will lead the Global Medical and Clinical Affairs team, amplifying clinician and patient voices within the organization. Fostering Collaboration and...

Continue Reading
MiningToken Revolutionizes Cryptocurrency With AI Power

Updated Category News Views 186

Introducing MiningToken's Innovative AI Cloud Mining Service Bitcoin and Ethereum are experiencing remarkable market dynamics as Bitcoin persists in a bullish trend and Ethereum has gained notable ground recently. As global interest in cryptocurrencies grows, effective mining strategies are crucial for profitability. Amidst rising operational costs, many individuals seek...

Continue Reading
Saluda Medical's EVA™ Sensing Technology Approved in Europe

Updated Category News Views 111

Saluda Medical Achieves Regulatory Milestone with EVA™ Technology Saluda Medical, Inc. (ASX:SLD) has made significant strides in the medical device industry by achieving CE certification for its next-generation EVA™ Sensing Technology. This advancement not only marks a major endorsement in Europe but also is recognized in Australia. Following FDA approval in December...

Continue Reading
ReadPartner Inc. Unveils Revolutionary AI Tool to Combat Misinformation

Updated Category News Views 291

ReadPartner Inc. Launches AI Feature to Tackle Misinformation ReadPartner Inc., a leader in AI-driven media intelligence solutions, is excited to announce the upcoming launch of a groundbreaking digital security feature named ProfileScreen. This innovative tool aims to address the pressing issue of misinformation that plagues social media platforms. The ProfileScreen...

Continue Reading